REGN
Regeneron is a biopharmaceutical company that harmonizes biology and technology to develop life-changing medicines. Its focus spans biologics and genetic medicines across oncology/hematology, inflammatory diseases, neuroscience, respiratory and other serious conditions, with operations and clinical development rooted in the United States and global collaborations. The company emphasizes research and development, clinical trials, and a commitment to responsible practices and patient access. Headquartered in the U.S., Regeneron positions itself at the intersection of science and medicine to bring therapies to patients worldwide.
No recent deals for this company.